Ramucirumab’s Overall Survival Advantage Disappointing: Analysts

Clinical Trials Advisor
A A
Eli Lilly’s cancer drug ramucirumab achieved a statistically significant but small overall survival advantage in a key gastric cancer trial, underwhelming analysts.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00